Welcome to BioSeeker Group!

Analytical Tool - Melanoma

Additional Information

Published Date Feb 21, 2012
Format PDF & Software Application
Publisher BioSeeker Group

Availability: In stock

€3,100.00

Quick Overview

This report offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D.
Request free sample pages from Analytical Tool - Melanoma

"Analytical Tool - Melanoma" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D and business development. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:


The Package Includes

  • A progress analysis on current and emerging drugs
  • Information on most companies active in melanoma R&D
  • Information on key industry related melanoma projects
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of melanoma therapeutics
  • Identifying emerging melanoma products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of melanoma drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Request free sample pages from Analytical Tool - Melanoma

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Cancer Immunotherapy
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer immunotherapy. Learn More


Analytical Tool - Cancer Therapeutic Antibodies
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development. Learn More

Other selected research from the 'R&D' category:


Vascular Targeting Agents: Emerging Competitors
An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More


TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
BioSeeker Group have identified 237 companies plus partners who are today developing 288 TGF-beta receptor pathway targeting drugs in 815 developmental projects in cancer across 165 different targets. In addition, there are 2 suspended drugs and another 172 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Lymphoma and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market
This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. Learn More